PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation
Journal article published in 2019 by
Zhihong Ren,
Jeong Hyun Ahn 
,
Hequn Liu,
Yi-Hsuan Tsai ,
Natarajan V. Bhanu,
Brian Koss,
David F. Allison,
Anqi Ma,
Aaron J. Storey ,
Ping Wang,
Samuel G. Mackintosh,
Ricky D. Edmondson,
Richard W. J. Groen,
Anton C. Martens,
Benjamin A. Garcia
and other authors.
,
Hequn Liu,
Yi-Hsuan Tsai ,
Natarajan V. Bhanu,
Brian Koss,
David F. Allison,
Anqi Ma,
Aaron J. Storey ,
Ping Wang,
Samuel G. Mackintosh,
Ricky D. Edmondson,
Richard W. J. Groen,
Anton C. Martens,
Benjamin A. Garcia
and other authors.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Abstract Polycomb repressive complex 2 (PRC2) dysregulation is associated with proliferation of hematological malignancies. Ren et al elucidate the mechanisms of PRC2 in multiple myeloma (MM), demonstrating that malignant progression of MM is associated with overexpression of PHF19, a PRC2-associated factor that enhances its gene-regulatory function.